Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) will release its third-quarter 2025 financial results on Tuesday, November 4, 2025 prior to the open of U.S. markets. Management will host a live webcast at 8:00 a.m. Eastern Time the same day to review financial and operating results.

Investors can access the live webcast via the company’s Investor Relations website and are advised to register at least 15 minutes before the start time. A replay will be available approximately two hours after the live webcast.

CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its third-quarter 2025 financial results on Tuesday, Nov. 4, 2025, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

When will Madrigal Pharmaceuticals (MDGL) release Q3 2025 results?

Madrigal will release its Q3 2025 financial results on Tuesday, November 4, 2025 prior to the U.S. market open.

What time is the Madrigal (MDGL) Q3 2025 webcast on November 4, 2025?

The live webcast is scheduled for 8:00 a.m. Eastern Time on November 4, 2025.

How can investors access the Madrigal (MDGL) Q3 2025 webcast?

Access the live webcast via the company’s Investor Relations website; registration is recommended at least 15 minutes before start.

Will Madrigal (MDGL) provide a replay of the November 4, 2025 webcast?

Yes. A replay will be available on the Investor Relations website approximately two hours after the live webcast.

Is Madrigal (MDGL) presenting financial results before or after U.S. market open on Nov 4, 2025?

The company will release results prior to the open of U.S. financial markets on November 4, 2025.